Isotope – Regional Alliance, Joint-Stock Company (Isotope JSC, part of Rosatom’s Scientific Division) will supply technetium-99m generator sets to the Kyrgyz Republic on a regular basis. The company will provide radiopharmaceutical products to the National Center of Oncology and Hematology in Bishkek within the framework of the national project of the technical cooperation program of the International Atomic Energy Agency (IAEA) “Restoration of Nuclear Medicine in Kyrgyzstan” and as part of the Agency’s “Rays of Hope” program.
The GT-5K type technetium-99 generators produce technetium-99, a radionuclide that is in high demand in nuclear medicine. Tehnetium-99 is employed in 80% of single-photon emission computed tomography (SPECT) procedures to diagnose a wide range of conditions, including cancer, heart, neuroendocrine and other diseases. SPECT makes it possible to visualize the thyroid, heart, bones, lungs, kidneys and gastrointestinal tract enabling the detection of metastases and other abnormalities at an early stage. This helps significantly improve the accuracy of diagnoses and the effectiveness of treatments and increase survival rates.
“The development of cooperation with the Kyrgyz Republic in the field of nuclear medicine is an important step towards improving access to advanced technologies and early detection of various health conditions. Through our joint efforts, we aim to enhance the quality of life for patients and reduce the number of deaths from cancer,” stated Maxim Kushnarev, Director General of Isotope JSC.
